RIPK1 and neoplasm: Their direct applicability to the complex tumour microenvironment in humans, and whether RIPK1-driven necroptosis constitutes a widespread and critical cell death pathway in human cancers, remain to be thoroughly validated using more specific tools and clinically relevant models.